Azaya Therapeutics Gets FDA Authorization For Study

San Antonio-based Azaya Therapeutics, which is developing new cancer treatments, said Thursday that it has received approval for starting a Phase I cancer trial of ATI-1123, the firm's new formulation of chemotherapy drug Taxotere. The firm said the FDA approved its Investigational New Drug (IND) application, and it will open enrollment for the study at the South Texas Accelerated Research Therapeutics at the START Center for Cancer Care in San Antonio and The Mary Crowley Cancer Research Center in Dallas. Azaya is backed by the Texas Emerging Technology Fund.